Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Forns

Showing results (171-180 of 298) with videos related to

Pageof 30
Sort By:
Arthritis Research & Therapy|September 16, 2015
How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patientsPilar Brito-Zerón, Hoda Gheitasi, Soledad Retamozo, et al.
Hepatology (Baltimore, Md.)|February 24, 2006
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantationAlejandro Blasco, Xavier Forns, José A Carrión, et al.
The Lancet. Gastroenterology & Hepatology|April 19, 2017
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trialTania M Welzel, Tarik Asselah, Emily O Dumas, et al.
Antiviral Therapy|June 9, 2006
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 8, 2015
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaXavier Forns, Fred Poordad, Marcos Pedrosa, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 28, 2015
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral TherapySabela Lens, Diego Rincón, Montserrat García-Retortillo, et al.
Hepatology (Baltimore, Md.)|June 5, 2013
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodiesJannie Pedersen, Thomas H R Carlsen, Jannick Prentoe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 22, 2019
Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodiesLaura-Patricia Llovet, Jordi Gratacós-Ginés, Oswaldo Ortiz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 7, 2020
Improvement of sexuality after hepatitis C cure with direct acting antiviralsZoe Mariño, Sergio Rodríguez-Tajes, Concepció Bartrés, et al.
Journal of Hepatology|April 17, 2016
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyMaría Reig, Zoe Mariño, Christie Perelló, et al.
Pageof 30

Showing results (171-180 of 298) with videos related to

Sort By:
Pageof 30
Arthritis Research & Therapy|September 16, 2015
How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patientsPilar Brito-Zerón, Hoda Gheitasi, Soledad Retamozo, et al.
Hepatology (Baltimore, Md.)|February 24, 2006
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantationAlejandro Blasco, Xavier Forns, José A Carrión, et al.
The Lancet. Gastroenterology & Hepatology|April 19, 2017
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trialTania M Welzel, Tarik Asselah, Emily O Dumas, et al.
Antiviral Therapy|June 9, 2006
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 8, 2015
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaXavier Forns, Fred Poordad, Marcos Pedrosa, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 28, 2015
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral TherapySabela Lens, Diego Rincón, Montserrat García-Retortillo, et al.
Hepatology (Baltimore, Md.)|June 5, 2013
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodiesJannie Pedersen, Thomas H R Carlsen, Jannick Prentoe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 22, 2019
Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodiesLaura-Patricia Llovet, Jordi Gratacós-Ginés, Oswaldo Ortiz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 7, 2020
Improvement of sexuality after hepatitis C cure with direct acting antiviralsZoe Mariño, Sergio Rodríguez-Tajes, Concepció Bartrés, et al.
Journal of Hepatology|April 17, 2016
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyMaría Reig, Zoe Mariño, Christie Perelló, et al.
Pageof 30